[Difficult-to-treat patients with chronic hepatitis C]

Area of Science:

• Hepatology
• Virology
• Pharmacology

Background:

• Pegylated interferon-alpha plus ribavirin is the standard hepatitis C treatment.
• Achieving undetectable HCV-RNA six months post-treatment is the primary goal.
• Difficult-to-treat patients include those with specific clinical factors, low response chances, prior treatment failures, intolerance, or poor compliance.

Purpose of the Study:

• To outline strategies for managing difficult-to-treat hepatitis C patients.
• To discuss treatment options for patients with low sustained virologic response (SVR) potential.
• To highlight the importance of experienced centers and new antiviral agents.

Main Methods:

• Review of current standard of care for hepatitis C.
• Identification and categorization of difficult-to-treat patient subgroups.
• Discussion of retreatment strategies and novel therapeutic approaches.
• Emphasis on active management of side effects and adherence optimization.

Main Results:

• Standard therapy may require dose adjustments or longer duration for some patients.
• Retreatment with higher doses or longer durations is an option for non-responders.
• Clinical trials of new antiviral agents offer hope for non-responders and intolerant patients.
• Active management of side effects and adherence are crucial for successful outcomes.

Conclusions:

• Management of difficult-to-treat hepatitis C requires individualized strategies.
• Retreatment and novel antiviral agents are key options for improving SVR.
• Comprehensive patient support, including side effect management and adherence optimization, is essential.